Compare HRB & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRB | CRSP |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | 1994 | 2016 |
| Metric | HRB | CRSP |
|---|---|---|
| Price | $37.19 | $54.91 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $41.00 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 2.1M | 1.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 3.38 | N/A |
| Revenue | ★ $3,159,931,000.00 | $289,590,000.00 |
| Revenue This Year | $4.39 | $807.72 |
| Revenue Next Year | $3.21 | $172.52 |
| P/E Ratio | $10.59 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $28.16 | $44.12 |
| 52 Week High | $56.76 | $78.48 |
| Indicator | HRB | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 53.13 |
| Support Level | $29.24 | $50.17 |
| Resistance Level | $39.96 | $60.10 |
| Average True Range (ATR) | 1.16 | 2.57 |
| MACD | -0.17 | 0.19 |
| Stochastic Oscillator | 66.77 | 60.16 |
H&R Block Inc provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block's offices are located in the U.S. The company derives the majority of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.